Articles
Meta-Analysis of Proptosis Response in Thyroid Eye Disease: Efficacy of EUGOGO Recommended Treatment Regimen With IV Methylprednisolone
- Journal/Conference:
- Journal of the Endocrine Society
- Author(s):
- Douglas, R. S., Batten, R., Qadeer, R.A., Cameron, C.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Vision
- Condition:
- Thyroid Eye Disease
Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain
- Journal/Conference:
- Expert Review of Pharmacoeconomics & Outcomes Research
- Author(s):
- Galan, L.: Gonzalez-Moreno, J.: Martínez-Sesmero, J.M.:Muñoz-Beamud, F.: Santos-Rubio, M.D.: Tran, D.: Lebeau, P.: Stewart, M.: Mallaina, P.: Tarilonte, P.: Peral, C.: Rozenbaum, M.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Nervous System
- Condition:
- Transthyretin amyloid polyneuropathy (ATTR-PN)
Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies
- Journal/Conference:
- European Heart Journal - Quality of Care and Clinical Outcomes
- Author(s):
- Rozenbaum, M.H.: Garcia, A.: Grima, D.: Tran, D.: Bhambri, R.: Stewart, M.: Li, B.; Heeg, B.: Postma, M.: Masri, A.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Cardiac
- Condition:
- ATTR cardiomyopathy
Annual Cardiovascular-related Hospitalization Days Avoided With Tafamidis Treatment in Patients With Transthyretin Amyloid Cardiomyopathy
- Journal/Conference:
- Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021 (Sept 10 - 13, 2021; Denver, CO)
- Author(s):
- Rozenbaum, M.: Tran, D.: Bhambri, R.: Nativi-Nicolau, J.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Cardiac
- Condition:
- ATTR cardiomyopathy
Modelling Lifetime Survival Gain in Patients With Transthyretin Amyloid Cardiomyopathy and Baseline NYHA Class III: An Analysis of ATTR-ACT and Long-Term Extension Study
- Journal/Conference:
- Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021 (Sept 10 - 13, 2021; Denver, CO)
- Author(s):
- Rozenbaum, M.: Tran, D.: Li, B.: Bhambri, R.: Postma, M.: Masri, A.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Cardiac
- Condition:
- ATTR cardiomyopathy
Efficacy classification of modern therapies in multiple sclerosis
- Journal/Conference:
- Journal of Comparative Effectiveness Research
- Author(s):
- Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, Häring DA, Stoneman D, Klotz L, Adlard N.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Nervous System
- Condition:
- Multiple Sclerosis
Network Meta-analysis of Disease-modifying Therapies for Relapsing Multiple Sclerosis Based on Confirmed Disability Progression: Investigating the Influence of Cross-trial Differences in Endpoint Definition
- Journal/Conference:
- 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 13-15 October 2021 [online]
- Author(s):
- Stoneman D, Drudge C, Zhao M, Worthington E, Cameron C, Haring DA, Samjoo I, Adlard N
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Nervous System
- Condition:
- Multiple Sclerosis
Relapse Reduction by Disease-modifying Therapies for Relapsing Multiple Sclerosis: A Network Meta-analysis
- Journal/Conference:
- 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 13-15 October 2021 [online]
- Author(s):
- Stoneman D, Drudge C, Zhao M, Worthington E, Cameron C, Haring D, Samjoo I, Adlard N
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Nervous System
- Condition:
- Multiple Sclerosis
Cost effectiveness of Ofatumumab in Comparison With Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
- Journal/Conference:
- ISPOR EU 2021
- Author(s):
- Thomas, K.; Adlard, N.; Cooney, P.; Blanchette, F.; Patel, BP.; Baharnoori, M.; Bhan, V.; Clift, F.; Grima, D.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Immune
- Condition:
- Relapsing-Remitting Multiple Sclerosis
Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
- Journal/Conference:
- PharmacoEconomics - Open
- Author(s):
- Bonifacio, M,: Maheshwari, V.: Tran, D.: Agostoni, G.: Filioussi, K.: Viana, R.
- Publication Date:
- 2021
- Topic/Therapeutic Area:
- Blood, Oncology
- Condition:
- chronic myeloid leukemia